One aim of analyzing BC patients with PT-HER2-neg but CTC-HER2/neu-pos characteristics was to investigate the hypothesis that a very few HER2-amplified cells do exist in the PT but are not detected by routine pathology and might explain the discrepancies in HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.